Go Deep
Abeona Therapeutics Inc.
Abeona Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,316 | -3.8 | 2.02 | 0.15 | 430.46 |
| Oct 2026 | 20,456 | -3.7 | 1.95 | 0.15 | 413.97 |
| Oct 2026 | 20,202 | -4.1 | 2.08 | 0.15 | 441.57 |
| Oct 2026 | 20,395 | -3.8 | 1.98 | 0.15 | 419.59 |
| Oct 2026 | 20,413 | -3.7 | 1.97 | 0.15 | 418.14 |
| Oct 2026 | 20,246 | -3.9 | 2.05 | 0.15 | 436.16 |
| Oct 2026 | 20,325 | -3.8 | 2.01 | 0.15 | 426.57 |
| Oct 2026 | 20,360 | -3.8 | 2.00 | 0.15 | 421.93 |
Abeona Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 11,380,000.0 | 8,720,000.0 | 5,420,000.0 | 0.0 |
| Net Profit | -20,191,000.0 | -17,075,000.0 | -20,460,000.0 | -5,161,000.0 |
| EPS | -0.3 | -0.3 | — | -0.1 |
Abeona Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 5,820,000.0 | 0.0 | 3,500,000.0 | 1,414,000.0 | — |
| Net Profit | 71,183,000.0 | -63,734,000.0 | -54,188,000.0 | -39,696,000.0 | — |
| EPS | 1.3 | -1.6 | -2.5 | -5.5 | — |
Abeona Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 219,570,000.0 | 108,931,000.0 | 64,002,000.0 | 64,214,000.0 | — |
| Total Liabilities | 60,354,000.0 | 64,900,000.0 | 49,176,000.0 | 37,453,000.0 | — |
| Total Equity | 159,216,000.0 | 44,031,000.0 | 14,826,000.0 | 26,761,000.0 | — |
Owes vs Owns
Abeona Therapeutics Inc. owed $0.29 for every $1 it owned in Jun 2026, down from $0.58 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.29× | 0.27× | 0.60× | 0.77× | 0.58× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Abeona Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 87.2%Receivables 3.1%Inventory 2.5%Fixed assets (tangible) 6.3%Other assets 0.9%
How it's funded — Dec 2025
Short-term debt 5.6%Long-term debt 3.6%Payables 3.6%Other liabilities 14.8%Shareholders' equity 72.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 191.4 | 97.7 | 52.2 | 52.1 |
| Receivables | 6.7 | 1.7 | 2.4 | 0.2 |
| Inventory | 5.5 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 13.9 | 8.0 | 8.0 | 11.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.1 | 1.6 | 1.3 | 0.8 |
| Liabilities & equity | ||||
| Short-term debt | 12.2 | 5.9 | 1.0 | 1.8 |
| Long-term debt | 7.8 | 13.0 | 4.4 | 5.9 |
| Payables | 7.9 | 3.4 | 1.9 | 1.8 |
| Other liabilities | 32.4 | 42.5 | 41.9 | 28.0 |
| Shareholders' equity | 159.2 | 44.0 | 14.8 | 26.8 |
| Net tangible assets | 159.2 | 44.0 | 14.8 | 26.8 |
Abeona Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -76,326,000.0 | -56,015,000.0 | -37,009,000.0 | -43,483,000.0 | — |
| Investing Activities | 105,028,000.0 | -39,240,000.0 | 208,000.0 | -23,964,000.0 | — |
| Financing Activities | 26,040,000.0 | 104,139,000.0 | 37,057,000.0 | 43,173,000.0 | — |